SEC Filing Summary: Capricor Therapeutics, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Capricor Therapeutics, Inc., a Delaware corporation, on December 19, 2017. The report serves to disclose a corporate presentation posted to the company's website regarding updates on its current business and products.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material financial changes versus a prior period are detailed in this filing. The primary event reported is the release of the "Corporate Presentation" (Exhibit 99.1) to investors.
Guidance, Outlook, and Risks
The filing incorporates by reference a corporate presentation containing business and product updates. The document explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section, except as expressly set forth by specific reference in other filings.
Key Facts for Investor Verification
- Verify the content of the attached "Corporate Presentation" (Exhibit 99.1) for specific business and product updates.
- Confirm that this 8-K filing does not constitute a formal filing of financial data under Section 18 of the Exchange Act.
- Note that the report was signed by Linda Marbán, Ph.D., Chief Executive Officer, on December 19, 2017.